A Randomized Phase III Trial Of Hypofractionated Post-Prostatectomy Radiation Therapy (HYPORT) Versus Conventional Post-Prostatectomy Radiation Therapy (COPORT)
Principal Investigator
Mark Buyyounouski, MD MS
Status
Closed to Accrual
Date Opened To Accrual
July 28 2017
Date Closed to Accrual
July 09 2018
Disease Site
Genitourinary [GU]
Prostate
Phase
III
Developmental Therapeutics
No
Primary Objective
The primary objective is to demonstrate that hypofractionated post-prostatectomy radiotherapy (HYPORT) does not increase patient-reported GI and GU symptoms over conventionally fractionated post-prostatectomy (COPORT) at the 2-year time point.
Patient Population
Patient Population
Patients with adenocarcinoma of the prostate treated primarily with radical prostatectomy; pathologic T-classification pT2 or pT3; pathologic N-classification pN0 or pNX; and no clinical evidence of regional lymph node metastasis.
Target Accrual
282
Patient Study Webpage
There is no available patient study webpage available for this trial at this time.